Kura Oncology's CEO, Wilson, has sold $327,000 worth of shares, which raises questions about the company's future direction and investor confidence. While insider selling can sometimes indicate a lack of faith in the company's prospects, it can also be a personal financial decision unrelated to the company's performance. This sale is noteworthy as it may influence market perceptions and investor sentiment regarding Kura Oncology.

Kura Oncology's Chief Commercial Officer, Powl, has sold $79,000 worth of shares in the company. This transaction is noteworthy as it reflects the ongoing activities of company executives in managing their stock holdings. Such sales can sometimes raise questions among investors about the company's future prospects, but they are also a common practice among executives.